Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events
Article first published online: 25 AUG 2013
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
European Journal of Immunology
Volume 43, Issue 11, pages 2930–2942, November 2013
How to Cite
Schouppe, E., Mommer, C., Movahedi, K., Laoui, D., Morias, Y., Gysemans, C., Luyckx, A., De Baetselier, P. and Van Ginderachter, J. A. (2013), Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur. J. Immunol., 43: 2930–2942. doi: 10.1002/eji.201343349
- Issue published online: 20 NOV 2013
- Article first published online: 25 AUG 2013
- Accepted manuscript online: 23 JUL 2013 12:58AM EST
- Manuscript Accepted: 17 JUL 2013
- Manuscript Revised: 10 JUN 2013
- Manuscript Received: 16 JAN 2013
- doctoral grant from FWO-Vlaanderen
- Stichting tegen Kanker
- Vlaamse Liga tegen Kanker
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Table S1. Overview of the effects of MO- and PMN-MDSCs on various aspects of CD8+ T-cell activation.
Table S2. List of commercial antibodies used for flow cytometry
Figure S1. MO- and PMN-MDSCs were purified from the spleens of EG7-OVA tumor-bearing WT, IFN-γR-/-, STAT-1-/- and IRF-1-/- mice.
Figure S2. MO- and PMN-MDSCs differentially depend on IFN-γ, STAT-1 and IRF-1 to activate their anti-proliferative capacity.
Figure S3. MO-MDSCs respond more heterogeneously to an IFN-γ challenge than PMN-MDSCs, as measured by STAT-1 phosphorylation.
Figure S4. Gating strategy on CD8+ OT-1 T cells after 24 h and 42 h culture.
Figure S5. PMN-MDSCs increase IFN-γ secretion levels upon co-culture with OVA-stimulated OT-1 splenocytes.
Figure S6. IFN-γR-/- and IRF-1-/- MDSCs enhance IFN-γ production by activated CD8+ T cells on a per cell basis.
Figure S7. MO- and PMN-MDSCs do not augment IL-12 levels upon co-culture with OVA-stimulated OT-1 splenocytes.
Figure S8. MO- and especially PMN-MDSCs suppress T-bet expression in activated CD8+ T cells.
Figure S9. MDSCs down-modulate IL-2 production by activated CD8+ T cells.
Figure S10. MO-MDSCs down-regulate CD25 expression and STAT5 phosphorylation.
Figure S11. MDSCs alter the expression levels of cell adhesion molecules on CD8+ T cells.
Figure S12. MO-MDSCs augment Fas expression on activated CD8+ T cells.
Figure S13. Neither MO- nor PMN-MDSCs are targets for OVA-specific CTLs, nor do they affect the cytotoxic activity of mature CTLs.
Figure S14. Unseparated splenic MDSCs affect CD8+ T-cell activation events.
Figure S15. RMA-OVA-induced splenic MDSCs affect CD8+ T-cell activation events.
Figure S16. MDSCs differentially affect CD8+ T-cell activation events upon polyclonal stimulation.
Figure S17. Tumor-infiltrating MO-MDSCs are strongly anti-proliferative and recapitulate only some aspects of their splenic counterparts.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.